# Managed Access Program for Momelotinib in Myelofibrosis

> **NCT05582083** · — · NO_LONGER_AVAILABLE · sponsor: **GlaxoSmithKline**

## Conditions studied

- Myelofibrosis
- Primary Myelofibrosis

## Interventions

- **DRUG:** Momelotinib

## Key facts

- **NCT ID:** NCT05582083
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05582083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05582083, "Managed Access Program for Momelotinib in Myelofibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05582083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*